SHR0302Base gel + SHR0302Base gel placebo

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Vitiligo

Conditions

Vitiligo

Trial Timeline

Feb 13, 2025 → Apr 1, 2026

NCT ID

NCT06790862

About SHR0302Base gel + SHR0302Base gel placebo

SHR0302Base gel + SHR0302Base gel placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Vitiligo. The current trial status is active. This product is registered under clinical trial identifier NCT06790862. Target conditions include Vitiligo.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06790862	Phase 2	Active	Feb 13, 2025	Apr 1, 2026	Vitiligo

Competing Products

20 competing products in Vitiligo

See all competitors

Product	Company	Stage	Hype Score
SHR0302 Tablets + SHR0302 Base Gel + SHR0302 Placebo Tablets + SHR0302 Base Placebo Gel	Jiangsu Hengrui Medicine	Phase 2	52
Upadacitinib + Placebo	AbbVie	Phase 3	77
Upadacitinib + Placebo	AbbVie	Phase 2	52
Anifrolumab Infusion Product + Placebo	AstraZeneca	Phase 2	52
MK-6194 + Placebo	Merck	Phase 2	52
Secukinumab	Novartis	Approved	85
Application of pimecrolimus	Novartis	Phase 2	52
GIA632 + Placebo	Novartis	Phase 2	52
AMG 714 + Placebo	Amgen	Phase 2	51
PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841	Pfizer	Phase 2	51
Ritlecitinib + Ritlecitinib + Placebo	Pfizer	Phase 3	76
Crisaborole 2 % Topical Ointment + PF-07038124 0.01% topical ointment + Vehicle	Pfizer	Phase 2	51
Ritlecitinib + Ritlecitinib 100 mg + Placebo	Pfizer	Phase 3	76
Ritlecitinib + Placebo	Pfizer	Phase 3	76
Abatacept	Bristol Myers Squibb	Phase 1	32
Ruxolitinib cream + Vehicle	Incyte	Phase 3	74
Ruxolitinib cream + Vehicle cream	Incyte	Phase 2	49
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
INCB054707 + Placebo	Incyte	Phase 2	49

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved